Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weigh
about
Investigational drugs to treat methicillin-resistant Staphylococcus aureusWill there ever be a universal Staphylococcus aureus vaccine?Synthetic teichoic acid conjugate vaccine against nosocomial Gram-positive bacteriaAnti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants.Antibodies to watch in 2010Postgenomic strategies in antibacterial drug discovery.Understanding the significance of Staphylococcus epidermidis bacteremia in babies and childrenNovel targeted immunotherapy approaches for staphylococcal infection.The potential economic value of a Staphylococcus aureus vaccine for neonatesHumanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycinAssessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.New insights into the prevention of staphylococcal infections and toxic shock syndrome.Isolation of highly active monoclonal antibodies against multiresistant gram-positive bacteria.An evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children.Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency.Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice.Generation and Improvement of Effector Function of a Novel Broadly Reactive and Protective Monoclonal Antibody against Pneumococcal Surface Protein A of Streptococcus pneumoniae.Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection.Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.Does IVIg administration yield improved immune function in very premature neonates?Novel agents to inhibit microbial virulence and pathogenicity.Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies.Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.Targeting the host-pathogen interface for treatment of Staphylococcus aureus infection.Immunoprophylaxis and immunotherapy of Staphylococcus epidermidis infections: challenges and prospects.Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Antibody-Based Agents in the Management of Antibiotic-Resistant Staphylococcus aureus Diseases.
P2860
Q26780246-ACE67F31-796B-498E-AF13-DE0B71DCB001Q26824837-7246C2B5-2B2D-4836-8F40-84DD0AC20AB9Q28543983-2E50B386-9B88-485E-86BB-445E7EBC4022Q30300455-7B61BA08-01A5-43DA-81F2-5948F9AB740EQ33688243-25EAABBA-8AF5-4D40-BA06-386839E7AEF3Q33745572-6EE3DE85-7E05-4685-9BED-0993ABAA9BD3Q33870497-7A3E8D8B-F483-4E1D-ACC0-9992773A5C4DQ33910565-81755E1F-9C83-4C6E-AF58-85CA4163F8A6Q33958347-BCA4E59E-1042-4C63-8370-11308B18D8D7Q34315661-D7FA9C0A-4C64-4BDE-84E8-A8CC9294F12DQ34999911-9E4B1768-05BC-4B76-A6C2-5FF7AB94DA8DQ35008802-2050B991-5EF9-42E5-8556-874873FC8121Q35112655-D98C9CD7-B393-4D04-A13D-6936B8B1804FQ35618211-236644E5-7812-4AD7-BC0F-B1AA235C833DQ35805321-3E28FAC1-0B50-4EB4-8822-03A11C09A644Q35939497-025AFDD8-7918-4FC9-BCE1-1DA5E4FEA080Q36015321-BBA6D33F-FA58-4C18-A8C3-82ABF73EB406Q36609408-4A20DCF1-848B-4632-8F9F-21E987B21700Q37297030-64D6ACB7-C1F0-46D9-A725-A0246D5CB1E2Q37332203-786933F3-9409-4CA4-94C9-5074F0D984A9Q37669728-BCDFBD09-29CD-4A7D-A39C-53BDBE567C3DQ37780752-1E280174-BA49-4995-9021-B057EDE9F856Q37810155-BE5639D7-9001-444B-9D5F-22B2C1D36DC0Q37879190-695F4E83-C459-491B-9ED8-C2C67E34AB30Q37957015-1EA2381E-31E6-4612-BD9A-75AE228CE70EQ37989572-B1CED43E-39BC-4A83-A6A0-6FBA466F9F83Q38291356-A37F5201-1668-48F1-87D6-6D45F4A97C49Q53702468-C33B0392-9974-47CE-8E5C-047D9CF577A5
P2860
Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weigh
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase 1/2 double-blind, placeb ...... tions, in very-low-birth-weigh
@nl
type
label
Phase 1/2 double-blind, placeb ...... tions, in very-low-birth-weigh
@nl
prefLabel
Phase 1/2 double-blind, placeb ...... tions, in very-low-birth-weigh
@nl
P2093
P2860
P3181
P356
P1476
Phase 1/2 double-blind, placeb ...... very-low-birth-weight neonates
@en
P2093
Gerald W Fischer
Helen M Thackray
James J Mond
Jennifer Fretz
John F Kokai-Kun
Joseph A Garcia-Prats
Joseph H Schneider
Leonard E Weisman
Mirjana Nesin
William G Kramer
P2860
P304
P3181
P356
10.1128/AAC.01565-08
P407
P577
2009-07-01T00:00:00Z